Pfizer Inc PFE

$30.52 +0.57 (1.90%)

Valuation

Market cap
170,705,248,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.66
Forward PE
10.00
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
45,485,400
Avg volume
31,695,838
Day's range
$30.14 – $30.67
Shares out
5,699,674,000
Stochastic %K
90%
Beta
0.32
Analysts
Sell
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

Outcomes Oct 31, 4:47 PM
$MRNA $PFE $JNJ $IBRX ….eureka! mRNA BAD. https://x.com/mercuryconsul/status/2116294593428017543?s=46
0 replies
BobJohnBuoy666 Oct 31, 2:05 PM
$PFE wants to break out so badly, third weekly close above 200EMA
0 replies
parcha Oct 31, 12:10 PM
https://www.cnbc.com/2026/10/30/jim-cramer-week-ahead-apple-amd-jobs-report.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension $AMD $PFE $AMGN $SMH Tuesday The midterm elections take center stage, with Cramer watching whether a shift in congressional control could threaten planned data center projects. He warned that growing political opposition to the facilities could delay construction and hurt companies whose growth depends heavily on AI infrastructure spending. However, he’s “not going to write off the data center entirely because there are plenty of states that will welcome them.” On the earnings front, Advanced Micro Devices reports, offering another important test for the semiconductor sector following Intel’s disappointing results. Cramer expects AMD to report better numbers than rival Intel. Drugmakers Pfizer and Amgen also report. Cramer said both could benefit from renewed investor enthusiasm for pharmaceutical stocks.
0 replies
framus_morrigan Oct 31, 9:01 AM
$PFE Monthly candles chart. Nice candle. Keep going!
3 replies
thatsolardude365 Oct 31, 12:54 AM
$PFE: Chantix payors filed 17,885 claims too, alongside 3.58M consumer ones, and A.B. Data had fully reviewed none by Sept. 28. Payments wait on the Effective Date after Oct. 14 final approval. Claims closed. Open Class Actions.
0 replies
Joker_brz Oct 31, 12:53 AM
$PFE I almost forgot about PFE in my porto.. Jesus finally movin.. don't jinx .. scratch the a$$..
0 replies
Dl71174 Oct 31, 12:32 AM
$INO $LLY $PFE $PGEN Conference call before Market opens 8:00 a.m. for the first FDA approved non surgical respiratory treatment. The approval caused the only other treatment $PGEN to collapse 27% after hours 👍 $INO
0 replies
RocroBio Oct 30, 10:15 PM 0 replies